Investigating how VEGF and Neuropilin-2 contribute to treatment resistance in aggressive breast cancer.
VEGF/Neuropilin-2 Signaling and Radioresistance in Triple-Negative Breast Cancer
This study is looking at how certain signals in triple-negative breast cancer might make it harder for radiation therapy to work, with the goal of finding new ways to treat this tough type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-10887394 on NIH RePORTER |
What this research studies
This research focuses on Triple-Negative Breast Cancer (TNBC), a particularly aggressive form of breast cancer that often does not respond well to standard treatments. The study aims to understand how the signaling pathways involving Vascular Endothelial Growth Factor (VEGF) and Neuropilin-2 (NRP2) contribute to the cancer's resistance to radiation therapy. By examining how these pathways affect the accumulation of reactive oxygen species (ROS) in cancer cells, researchers hope to identify new therapeutic targets. The use of advanced techniques like single-cell RNA sequencing will help pinpoint specific subpopulations of TNBC that are resistant to treatment, potentially leading to more effective strategies for overcoming this resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Triple-Negative Breast Cancer who are undergoing or have undergone radiation therapy.
Not a fit: Patients with other types of breast cancer or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with Triple-Negative Breast Cancer, potentially reducing recurrence rates and enhancing therapeutic efficacy.
How similar studies have performed: While the specific approach of targeting the VEGF/NRP2 signaling pathway in TNBC is relatively novel, similar strategies targeting cancer resistance mechanisms have shown promise in other studies.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Kumar, Ayush — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Kumar, Ayush
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.